Koji Izutsu: clinical trial contracts with AbbVie, AstraZeneca, Beigene, Celgene, Chugai Pharmaceutical, Janssen, Novartis and Yakult; and honoraria for lectures from Janssen, AbbVie, Novartis, Celgene, AstraZeneca and Chugai Pharmaceutical. Kazuhito Yamamoto: grants from IQVIA/Genmab, Ono Pharmaceutical, Solasia Pharma, Yakult and Incyte; grants and personal fees from AbbVie, Astra-Zeneca, Bristol-Myers Squibb/Celgene, Chugai Pharmaceutical, Eisai, Meiji Seika Pharma, Nippon Shinyaku, Novartis, Otsuka Pharmaceutical, Takeda and Zenyaku; personal fees from SymBio, HUYA/IQVIA Services Japan, Janssen, Kyowa Kirin, Micron/Daiichi-Sankyo, MSD, Sanofi, Nippon Kayaku and Astellas. Koji Kato: consulting fees from AbbVie, AstraZeneca, Celgene, Chugai Pharmaceutical, Eisai, Janssen, Daiichi Sankyo, Ono Pharmaceutical and Novartis; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Bristol Myers Squibb, Celgene, Dainippon-Sumitomo, Janssen, Kyowa Kirin, MSD, Mundipharma, Ono Pharmaceutical, Takeda, AbbVie, Daiichi Sankyo, Eisai and Chugai Pharmaceutical. Takayuki Ishikawa: grants from AbbVie. Noriko Fukuhara: research grants from AbbVie, Bayer, Chugai Pharmaceutical, Celgene, Genmab and Incyte; and honoraria from AstraZeneca, BMS, Chugai Pharmaceutical, CSL Behring, Dainippon Sumitomo, Eisai, Janssen, Kyowa Kirin, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Sanofi, Symbio, Takeda and Zenyaku; and data safety monitoring board for HUYA Japan; and advisory board for AstraZeneca, AbbVie, Eli Lilly, Genmab and Novartis. Yasuhito Terui: consultant/adviser/honoraria from Celgene, Janssen, Eisai, Ono Pharmaceutical, Chugai Pharmaceutical, Symbio and AbbVie; and research grants from AbbVie, Bristol Myers Squibb; and scholarship funds from Ono Pharmaceutical, Eisai and Takeda. IIseung Choi: grants from AbbVie. Sumiko Okubo, Natsumi Ogawa, Mizu Sakai, Yasuko Nishimura, Brenda J Chyla, and Yan Sun: Employees of AbbVie and possible ownership of stocks or options. Dai Maruyama: honoraria from Ono Pharmaceutical, Celgene, Takeda, Janssen, Mundipharma, Eisai, Chugai Pharmaceutical, Kyowa Kirin, MSD, Zenyaku, Bristol Myers Squibb, AstraZeneca, Nippon Shinyaku, AbbVie, Sanofi and SymBio; research grants from Amgen Astellas Biopharma, Celgene, Kyowa Kirin, Novartis, Chugai Pharmaceutical, Ono Pharmaceutical, Takeda, Janssen, Sanofi, MSD, Otsuka Pharmaceutical, Bristol Myers Squibb, Astellas, Eisai and AbbVie; and scholarship funds from Taiho, Chugai Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin and Eisai.